EUVIMEDEUVIMED entdecken
Crossref

Mechanistic Insights and Clinical Evidence for Silymarin in the Management of Metabolic Dysfunction–Associated Fatty Liver Disease

Yuyao Xie, Hongli Xu, Tingshu Li, Ji Sun, Yiling Li

BioMed and BioSci Advances · 01.03.2026 · 01-15

DOI: 10.69626/bba.2026.0001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioMed and BioSci Advances, online erschienen am 01.03.2026. Verfasst von Yuyao Xie und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a growing global health challenge, characterized by hepatic steatosis, inflammation, and fibrosis in the setting of metabolic syndrome. Its pathogenesis is driven by insulin resistance, disordered lipid metabolism, and oxidative stress, often progressing to steatohepatitis (MASH) and cirrhosis. Silymarin, a flavonoid-rich extract derived from Silybum marianum, has attracted considerable interest for its multi-target hepatoprotective properties. This review summarizes the pharmacological mechanisms by which silymarin exerts antioxidant, anti-inflammatory, anti-fibrotic, and lipid-modulating effects, thereby addressing key pathways in MAFLD development. Clinical evidence indicates that silymarin, particularly in bioavailable complex formulations, significantly improves liver enzyme profiles, lipid parameters, and imaging findings in MAFLD patients. Combination regimens with agents such as vitamin E or statins appear to enhance therapeutic efficacy. Despite promising data, broader clinical adoption requires further large-scale, rigorous trials to standardize dosing, confirm long-term benefits, and validate safety in heterogeneous patient populations. Overall, silymarin emerges as a promising adjunctive natural compound in the integrated management of MAFLD.

Zitieren

APA

Xie, Y., Xu, H., Li, T., Sun, J., & Li, Y. (2026). Mechanistic Insights and Clinical Evidence for Silymarin in the Management of Metabolic Dysfunction–Associated Fatty Liver Disease. BioMed and BioSci Advances, 01-15. https://doi.org/10.69626/bba.2026.0001

Vancouver

Xie Y, Xu H, Li T, Sun J, Li Y. Mechanistic Insights and Clinical Evidence for Silymarin in the Management of Metabolic Dysfunction–Associated Fatty Liver Disease. BioMed and BioSci Advances. 2026:01-15. doi:10.69626/bba.2026.0001

BibTeX
@article{Xie2026,
  author = {Xie, Yuyao and Xu, Hongli and Li, Tingshu and Sun, Ji and Li, Yiling},
  title = {Mechanistic Insights and Clinical Evidence for Silymarin in the Management of Metabolic Dysfunction–Associated Fatty Liver Disease},
  journal = {BioMed and BioSci Advances},
  year = {2026},
  pages = {01--15},
  doi = {10.69626/bba.2026.0001}
}
Kostenlos starten →